[194 Pages Report] Retinal biologics market revenue totaled US$ 19.96 Billion in 2021. The global market is expected to reach US$ 41.92 Billion by 2028, surging at a CAGR of 11.1% over the period of 2022 to 2028.
| Attribute | Details |
|---|---|
| Retinal Biologics Market Size (2022) | US$ 22.25 Billion |
| Sales Forecast (2028) | US$ 41.92 Billion |
| Global Market Growth Rate (2022 to 2028) | 11.1% CAGR |
| Share of Top 5 Players | 50% |
Retinal biologics accounted for 6.9% share of the global biologic therapeutics market in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 11.08% |
| H1, 2022 Projected | 11.14% |
| H1, 2022 Outlook | 10.94% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 14 ↓ |
According to Future Market Insights' analysis, the global retinal biologics market expects to drop by 14 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 20 BPS.
The availability of very few retinal biologics, their severe side effects, rigorous regulatory standards involved with obtaining biologics approvals, and the exorbitant cost of effective drugs and biologics are all contributing factors to the drop in BPS values.
The market will however witness a positive growth outlook over the forecast period, owed to the increasing intensive research activities for the production of novel biologics for novel disease therapeutics.
The key development in the market includes innovations in ocular drug delivery to the retina with the development of intravitreal drugs. The retinal biologics market is subject to macroeconomic and industrial factors in accordance to stringent regulatory standards and approval activities for biologics.
“Rising Burden of Retinal Diseases to Boost Overall Market Growth”
From 2013 to 2021, the global retinal biologics market registered significant gains, experiencing a CAGR worth 10.2%
Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used for retinal diseases are Eylea, Lucentis, Humira, Macugen, and others.
Increased frequency of retinal diseases such as age-related macular degeneration around the world is driving the market expansion. According to WHO statistics, nearly 2.2 billion individuals worldwide suffer from near or distance vision impairment. As the prevalence of vision impairment rises, the need for effective therapeutic alternatives, such as retinal biologics, is rising as well.
Retinal biologics are a new class of medications that target specific markers in the patient's body to alleviate the symptoms of a variety of systemic or ocular disorders that present in the eye.
Considering these factors, the market is projected to witness high growth over the forecast period, registering an impressive CAGR of 11.1% to reach US$ 41.92 Bn by 2028.
“Rising R&D Activities in Retinal Gene Therapies to Fuel Market Expansion”
The market will be driven by a strong focus on R&D connected with retinal gene therapies conducted by different institutes, biologics firms, and innovative product releases by prominent market participants in the form of biologics and implants. Efforts to develop a complementary therapeutic treatment will boost the market growth.
“Market Growth Complemented by Increasing Burden of Retinal Diseases”
Diabetic retinopathy has been a rising concern as the disease leads to vision loss among type I and type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of the macula. Moreover, increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging demand for retinal drugs and biologics.
Retinal gene therapy is a therapeutic approach wherein inherited defective genes are replaced by treatment with DNA or RNA. Retinal gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes.
“Regulatory Obstructions Likely to Hinder Demand for Retinal Biologics”
Limited availability of retinal biologics, hazardous biologic side effects, and limited access for retinal biologics and efficient treatments due to higher costs are restraining the market growth.
The market is being challenged by the side effects of retinal biologics, which include retinal tear, sickness, and eye pain. Governing authorities' strict regulatory compliances associated with biologics approval are impeding industry growth.
Principal Consultant
“Ongoing Advancements in Biologics for Retinal Treatment”
North America is expected to have a significant share in the global retinal biologics market. Continuous improvements in healthcare infrastructure, as well as an increase in the number of cases of retinal illnesses and favorable reimbursement policies, are expected to promote market expansion in the region.
Prominent presence of key manufacturers and increased healthcare spending are driving market growth in the region. Growing diabetes population is a major driver in the development of biologics for retinal treatment in North America.
“Increased Prevalence of Diabetic Macular Edema to Augment Demand for Retinal Biologics”
Diabetic retinopathy is a disease that affects people who have diabetes. Diabetic retinopathy is the major cause of new incidents of blindness in adults aged 20 to 74 years in the United States.
According to a new research study released by the Centers for Disease Control and Prevention, more than 100 million persons in the United States currently have diabetes or prediabetes.
In addition, researchers are working on innovative strategies to treat diabetic macular edema. As a result, rising R&D spending in the country as well as risk factors that contribute to disease development will have an impact on the retinal biologics market in the U.S. over the forecast period.
“Rising Efforts for Development of Retinal Drugs to Drive Market Growth.”
The market in China is expected to grow due to rapidly rising cases of uveitis, diabetic retinopathy, and macular degeneration. Diabetes is exacerbated by a shift in lifestyle and an increase in bad eating habits, as a result of these factors, the global market for retinal drugs and biologics is expected to expand significantly.
Along with increasing incidence of eye diseases, there are a growing number of research initiatives focused on retinal drugs. Furthermore, growing geriatric population, which is becoming a target patient pool for retinal biologics, will boost market growth in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“VEGF-A Antagonists Most Preferred as They are Largely Tolerated & Give Instant Results to Eye Disorders.”
VEGF-A antagonists are used to treat eye damage and enhance corneal wound healing. The global retinal biologics market is also expected to be fueled by the rising prevalence of other retinal illnesses such as orbital inflammation and uveitis.
VEGF-A antagonists are commonly given for the treatment of diabetic retinopathy and diabetic macular edema. In the case of non-infectious uveitis, it is seen to be the ideal alternative to typical suppressing treatments.
Many firms have focused on VEGF-A antagonists because they reduce angiogenesis. Manufacturers are investing in the development of retinal biologics in a similar field due to the widespread acceptance of VEGF-A antagonist therapy.
“Increasing Adoption of Retinal Biologics for Macular Degeneration Treatment”
Macular degeneration indication is expected to account 36.9% share of the retinal biologics market in 2022. Macular Degeneration is a vision loss condition that affects the macula.
Despite the availability of improved treatment alternatives, the global retinal biologics market is likely to benefit from the increased prevalence of macular degeneration. According to the American Macular Degeneration Foundation, the prevalence is higher than the combined rates of cataracts and glaucoma in over 10 million Americans (AMDF).
Because macular degeneration primarily affects adults aged 50 and over, the prevalence of MD continues to go up, despite improving treatment choices, as the population ages.
The COVID-19 pandemic has had a massive effect on the worldwide healthcare system, resulting in a decreased focus on retinal biologics. The COVID-19 pandemic has disrupted global care patterns and prompted broad modifications in disease management across a wide range of therapeutic disciplines. Ophthalmology was one of the first areas to be affected.
The retinal biologics industry is expected to recover soon, owing to an increase in research efforts and significant government support. The importance of treatments and disease control protocols may increase demand for retinal biologics over the coming years
Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in US$ Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered | Drug Class, Indication, Distribution Channel, Region |
| Key Companies Profiled | Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc. |
| Pricing | Available upon Request |
Retinal Biologics Market by Drug Class:
Retinal Biologics Market by Indication:
Retinal Biologics Market by Distribution Channel:
Retinal Biologics Market by Region:
The global retinal biologics market is estimated to exhibit a CAGR of 11.1% during the forecast period (2022-2028).
Macular degeneration accounts for 36.9% share of the retinal biologics market.
The global retinal biologics market is expected to reach a valuation of US$ 41.92 Bn by 2028.
Increasing prevalence of diabetic eye diseases and significant R&D investments for developing biologics are key trends driving market growth.
Major players operating in the market include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., AbbVie Inc., and Amgen Inc.
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Global Economic Outlook 3.1. Gross Domestic Indication Type by Region & Country, 2006 – 2021 3.2. Global Healthcare Market Indicators 4. Market Opportunity Analysis 4.1. Macro-Economic Factors 4.2. Opportunity Analysis 5. Market Dynamics 5.1. Drivers 5.1.1. Supply Side Drivers 5.1.2. Demand Side Drivers 5.2. Restraints 5.3. Trends 6. Key Inclusion 6.1. Key Regulations 6.2. Reimbursement Scenario 6.3. Pricing Analysis 7. North America Market Analysis 2013–2021 and Forecast 2022–2028 7.1. Introduction 7.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 7.2.1. U.S. 7.2.2. Canada 7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 7.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 7.4.1. VEGF-An antagonist 7.4.2. TNF-α inhibitor 7.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 7.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 7.6.1. Macular Degeneration 7.6.2. Diabetic Retinopathy 7.6.3. Diabetic Macular Edema 7.6.4. Uveitis 7.6.5. Others 7.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 7.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021 7.8.1. Institutional Sales 7.8.1.1. Specialty Clinics 7.8.1.2. Hospitals 7.8.2. Retail Sales 7.8.2.1. Retail Pharmacies 7.8.2.2. Mail Order Pharmacies 7.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 7.10. Market Attractiveness Analysis 7.10.1. By Country 7.10.2. By Drug Class 7.10.3. By Indication 7.10.4. By Distributional Channel 7.11. Drivers and Restraints: Impact Analysis 7.12. Key Market Participants – Intensity Mapping 8. Latin America Market Analysis 2013–2021 and Forecast 2022–2028 8.1. Introduction 8.2. Regional Market Trends 8.3. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 8.3.1. Brazil 8.3.2. Mexico 8.3.3. Argentina 8.3.4. Rest of Latin America 8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 8.5. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 8.5.1. VEGF-A antagonist 8.5.2. TNF-α inhibitor 8.6. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 8.7. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 8.7.1. Macular Degeneration 8.7.2. Diabetic Retinopathy 8.7.3. Diabetic Macular Edema 8.7.4. Uveitis 8.7.5. Others 8.8. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 8.9. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021 8.9.1. Institutional Sales 8.9.1.1. Specialty Clinics 8.9.1.2. Hospitals 8.9.2. Retail Sales 8.9.2.1. Retail Pharmacies 8.9.2.2. Mail Order Pharmacies 8.10. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 8.11. Market Attractiveness Analysis 8.11.1. By Country 8.11.2. By Drug Class 8.11.3. By Indication 8.11.4. By Distributional Channel 8.12. Drivers and Restraints: Impact Analysis 8.13. Key Market Participants – Intensity Mapping 9. Western Europe Market Analysis 2013–2021 and Forecast 2022–2028 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 9.2.1. Germany 9.2.2. U.K 9.2.3. France 9.2.4. Italy 9.2.5. Spain 9.2.6. Rest of Western Europe 9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 9.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 9.4.1. VEGF-A antagonist 9.4.2. TNF-α inhibitor 9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 9.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 9.6.1. Macular degeneration 9.6.2. Diabetic Retinopathy 9.6.3. Diabetic Macular Edema 9.6.4. Uveitis 9.6.5. Others 9.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 9.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021 9.8.1. Institutional Sales 9.8.1.1. Specialty Clinics 9.8.1.2. Hospitals 9.8.2. Retail Sales 9.8.2.1. Retail Pharmacies 9.8.2.2. Mail Order Pharmacies 9.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 9.10. Market Attractiveness Analysis 9.10.1. By Country 9.10.2. By Drug Class 9.10.3. By Indication 9.10.4. By Distributional Channel 9.11. Drivers and Restraints: Impact Analysis 9.12. Key Market Participants – Intensity Mapping 10. Eastern Europe Market Analysis 2013–2021 and Forecast 2022–2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 10.2.1. Russia 10.2.2. Poland 10.2.3. Rest of Eastern Europe 10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 10.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 10.4.1. VEGF-A antagonist 10.4.2. TNF-α inhibitor 10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 10.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 10.6.1. Macular degeneration 10.6.2. Diabetic Retinopathy 10.6.3. Diabetic Macular Edema 10.6.4. Uveitis 10.6.5. Others 10.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 10.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021 10.8.1. Institutional Sales 10.8.1.1. Specialty Clinics 10.8.1.2. Hospitals 10.8.2. Retail Sales 10.8.2.1. Retail Pharmacies 10.8.2.2. Mail Order Pharmacies 10.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 10.10. Market Attractiveness Analysis 10.10.1. By Country 10.10.2. By Drug Class 10.10.3. By Indication 10.10.4. By Distributional Channel 10.11. Drivers and Restraints: Impact Analysis 10.12. Key Market Participants – Intensity Mapping 11. Asia Pacific Excluding Japan Market Analysis 2013–2021 and Forecast 2022–2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 11.2.1. China 11.2.2. India 11.2.3. Australia and New Zealand 11.2.4. ASEAN 11.2.5. Rest of APEJ 11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 11.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 11.4.1. VEGF-A antagonist 11.4.2. TNF-α inhibitor 11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 11.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 11.6.1. Macular degeneration 11.6.2. Diabetic Retinopathy 11.6.3. Diabetic Macular Edema 11.6.4. Uveitis 11.6.5. Others 11.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 11.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021 11.8.1. Institutional Sales 11.8.1.1. Specialty Clinics 11.8.1.2. Hospitals 11.8.2. Retail Sales 11.8.2.1. Retail Pharmacies 11.8.2.2. Mail Order Pharmacies 11.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 11.10. Market Attractiveness Analysis 11.10.1. By Country 11.10.2. By Drug Class 11.10.3. By Indication 11.10.4. By Distributional Channel 11.11. Drivers and Restraints: Impact Analysis 11.12. Key Market Participants – Intensity Mapping 12. Japan Market Analysis 2013–2021 and Forecast 2022–2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 12.2.1. VEGF-A antagonist 12.2.2. TNF-α inhibitor 12.3. Market Size (US$ Mn) and Forecast By Drug Class, 2022-2028 12.4. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 12.4.1. Macular degeneration 12.4.2. Diabetic Retinopathy 12.4.3. Diabetic Macular Edema 12.4.4. Uveitis 12.4.5. Others 12.5. Market Size (US$ Mn) Forecast By Indication, 2022-2028 12.6. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021 12.6.1. Institutional Sales 12.6.1.1. Specialty Clinics 12.6.1.2. Hospitals 12.6.2. Retail Sales 12.6.2.1. Retail Pharmacies 12.6.2.2. Mail Order Pharmacies 12.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 12.8. Market Attractiveness Analysis 12.8.1. By Drug Class 12.8.2. By Indication 12.8.3. By Distributional Channel 12.9. Drivers and Restraints: Impact Analysis 12.10. Key Market Participants – Intensity Mapping 13. Middle East and Africa Market Analysis 2013–2021 and Forecast 2022–2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021 13.2.1. GCC Countries 13.2.2. South Africa 13.2.3. Rest of Middle East and Africa 13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 13.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021 13.4.1. VEGF-A antagonist 13.4.2. TNF-α inhibitor 13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 13.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021 13.6.1. Macular degeneration 13.6.2. Diabetic Retinopathy 13.6.3. Diabetic Macular Edema 13.6.4. Uveitis 13.6.5. Others 13.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028 13.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021 13.8.1. Institutional Sales 13.8.1.1. Specialty Clinics 13.8.1.2. Hospitals 13.8.2. Retail Sales 13.8.2.1. Retail Pharmacies 13.8.2.2. Mail Order Pharmacies 13.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 13.10. Market Attractiveness Analysis 13.10.1. By Country 13.10.2. By Drug Class 13.10.3. By Indication 13.10.4. By Distributional Channel 13.11. Drivers and Restraints: Impact Analysis 13.12. Key Market Participants – Intensity Mapping 14. Forecast Factors: Relevance and Impact 15. Forecast Assumptions 16. Competition Analysis 16.1. Competition Dashboard 16.2. Competitors Deep Dive 16.2.1. Spark Therapeutics Inc. 16.2.1.1. Overview 16.2.1.2. Key Financials 16.2.1.3. SWOT Analysis 16.2.1.4. Key Developments 16.2.1.5. Key Strategy 16.2.2. F. Hoffmann-La Roche Ltd 16.2.2.1. Overview 16.2.2.2. Key Financials 16.2.2.3. SWOT Analysis 16.2.2.4. Key Developments 16.2.2.5. Key Strategy 16.2.3. Regeneron Pharmaceuticals, Inc. 16.2.3.1. Overview 16.2.3.2. Key Financials 16.2.3.3. SWOT Analysis 16.2.3.4. Key Developments 16.2.3.5. Key Strategy 16.2.4. AbbVie Inc 16.2.4.1. Overview 16.2.4.2. Key Financials 16.2.4.3. SWOT Analysis 16.2.4.4. Key Developments 16.2.4.5. Key Strategy 16.2.5. Johnson & Johnson Services, Inc 16.2.5.1. Overview 16.2.5.2. Key Financials 16.2.5.3. SWOT Analysis 16.2.5.4. Key Developments 16.2.5.5. Key Strategy 16.2.6. Amgen Inc. 16.2.6.1. Overview 16.2.6.2. Key Financials 16.2.6.3. SWOT Analysis 16.2.6.4. Key Developments 16.2.6.5. Key Strategy 17. Global Market Analysis 2013–2021 and Forecast 2022–2028 by Region 17.1. Introduction / Key Findings 17.2. Historical Market Size (US$ Mn) Analysis by Region 17.2.1. North America 17.2.2. Latin America 17.2.3. Western Europe 17.2.4. Eastern Europe 17.2.5. Asia Pacific Excluding Japan 17.2.6. Japan 17.2.7. Middle East and Africa 17.3. Market Size (US$ Mn) Forecast By Region 17.4. Market Attractiveness Analysis by Region 18. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class 18.1. Introduction/Key Finding 18.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2013-2021 18.2.1. VEGF-A antagonist 18.2.2. TNF-α inhibitor 18.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 18.4. Market Attractiveness Analysis by Drug Class 19. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Indication 19.1. Introduction/Key Finding 19.2. Historical Market Size (US$ Mn) Analysis by Indication, 2013-2021 19.2.1. Macular degeneration 19.2.2. Diabetic Retinopathy 19.2.3. Diabetic Macular Edema 19.2.4. Uveitis 19.2.5. Others 19.3. Market Size (US$ Mn) Forecast By Indication, 2022-2028 19.4. Market Attractiveness Analysis by Indication 20. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Distributional Channel 20.1. Introduction/Key Finding 20.2. Historical Market Size (US$ Mn) Analysis by Distributional Channel, 2013-2021 20.2.1. Institutional Sales 20.2.1.1. Specialty Clinics 20.2.1.2. Hospitals 20.2.2. Retail Sales 20.2.2.1. Retail Pharmacies 20.2.2.2. Mail Order Pharmacies 20.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028 20.4. Market Attractiveness Analysis by Distributional Channel 21. Global Market Analysis 2013–2021 and Forecast 2022–2028 21.1. Global Market Value Analysis (US$ Mn) 21.2. Absolute $ Opportunity 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Retinal Biologics Market
